Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage: a FinIP Effectiveness Trial Satellite Study During PCV National Vaccination Programme [SUBSTUDY OF 700042614]

Trial Profile

Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage: a FinIP Effectiveness Trial Satellite Study During PCV National Vaccination Programme [SUBSTUDY OF 700042614]

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs Pneumococcal 10-valent vaccine conjugate (Primary)
  • Indications Pneumococcal infections; Pneumonia
  • Focus Pharmacodynamics
  • Acronyms FinIP-carriage
  • Most Recent Events

    • 12 Jul 2017 Primary endpoint (Carriage due to any pneumococcal serotype included in the ten-valent pneumococcal conjugate vaccine (PCV10) in children vaccinated in infancy) has been met, according to the results published in the Pediatric Infectious Disease Journal
    • 12 Jul 2017 Results assessing Direct and Indirect Effectiveness of the Ten-Valent Pneumococcal Conjugate Vaccine Against Carriage in three FinIP trials (FinIP, FinIPcarr and FinIP-carriage) published in the Pediatric Infectious Disease Journal
    • 29 Mar 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top